Cardiovascular research runs the full spectrum, from Phase II mechanistic studies to large multi-year outcomes trials. Castor’s unified EDC and RWE platform handles multi-site coordination, registry data, and parallel RCT and RWE programs without the data entry burden that slows high-volume cardiology sites.
Large Phase III cardiovascular outcomes trials often involve hundreds of sites across dozens of countries. Managing site coordination, data quality, and protocol consistency at that scale requires infrastructure built for it, not adapted from smaller-trial tools.
Cardiovascular research increasingly runs RCT and RWE programs in parallel, sometimes from the same patient cohort. Managing two separate systems creates reconciliation overhead, data quality risks, and regulatory complexity. A unified platform eliminates this.
Cardiology sites generate enormous documentation volume. Manual data entry from hospital systems into EDC creates delays, errors, and staff burnout. Catalyst-automated ingestion from source systems eliminates the manual step.
Cardiovascular outcomes trials frequently run 5-10 years with complex adjudication requirements. The platform must maintain data integrity, audit trail completeness, and site engagement across a multi-year arc.
Cardiovascular research spans a wider range of study designs than almost any other therapeutic area, from tightly controlled Phase II mechanistic studies to large multi-year outcomes trials. The operational demands at each end of that spectrum are fundamentally different, yet sponsors often need a single platform to handle both.
From Phase II mechanistic studies to large-scale outcomes registries, Castor is designed for the scale, automation, and compliance that cardiovascular research demands.
Castor Catalyst‘s AI extraction layer turns uploaded site source documents (PDFs, EHR exports, and paper worksheets) into regulator-grade eCRF data, with human review. For patient-mediated data, Catalyst supports Direct-to-Patient retrieval where the patient authorizes FHIR access. Up to 80% reduction in data entry costs. 0% transcription error rate versus 6.6% industry average. Registries can go live in under 2 weeks. The Omnia BEACON study reduced data extraction time from 40 hours to under 4 hours per patient using Catalyst. See how clinical trial solutions built around Catalyst automation change what is operationally possible for high-volume cardiology sites.
Castor unifies EDC for interventional trials and RWE/registry data collection on a single validated platform. No separate system for your registry, no reconciliation between EDC and RWE databases, no additional regulatory burden for running both in parallel. 90%+ patient retention in Castor’s RWE studies. Your cardiovascular real-world evidence program and your Phase III RCT share the same compliance infrastructure from the first protocol version.
360+ cardiovascular and vascular trials have run on Castor, proven at scale and at clinical depth. At scale, a decentralized cardiovascular screening cohort of 20,900+ participants captured high-frequency digital health and remote screening data on the platform. At clinical depth, a 5,400+ patient coronary artery disease (CAD) study ran across 28 sites and an 8,400+ patient multi-center mitral valve disease study ran on Castor. WHO Solidarity demonstrates cross-TA scale proof for multi-country infrastructure reliability. Your Phase III outcomes program needs an electronic data capture system that has already operated at the patient volumes and site counts you are planning for.
Across 360+ cardiovascular and vascular trials, Castor coordinates large cardiology networks at scale. Multi-site dashboards give operational teams real-time visibility across every site without querying individual sites for status. The heaviest burden on cardiology coordinators is source-data entry, and Castor Catalyst removes most of it. The AI extraction layer turns uploaded site source documents into audit-ready eCRF data with human review, so coordinators spend less time transcribing and more time on patients. That capacity matters most for the real-world evidence programs running alongside large cardiovascular RCTs.
Castor scopes each study build with managed Professional Services. Low-to-medium complexity studies typically move from kickoff (KOM) to user acceptance testing (UAT) in 4 to 8 weeks. High-complexity studies take 8 to 12 weeks. Lighter-weight registries can deploy faster. No infrastructure to stand up, no per-site software installation, no IT project required. For sponsors running decentralized clinical trials or parallel cardiovascular programs, the build is scoped to the complexity of your protocol from kickoff.
FDA 21 CFR Part 11, ICH E6(R2/R3), EU Annex 11, HIPAA, GDPR, EU MDR PMCF. For cardiovascular medical device trials requiring post-market clinical follow-up under EU MDR, Castor handles the data collection infrastructure. Multi-region hosting with national data sovereignty controls. Greater than 99.9% historic mean uptime. 830 million+ data points captured on the platform. For programs that need eCOA solutions alongside EDC under a single validated compliance layer, Castor removes the integration overhead that separate-system approaches create. The regulatory stack is built in, not assembled per-program.
Planned for 2026: a Site Gateway de-identification capability that removes patient identifiers at the point of site upload, planned for 2026, to help address GDPR concerns when sites contribute source documents.
Cardiovascular and vascular trials on Castor, plus large-scale registries and RWE studies. 360+ cardiovascular and vascular trials have run on Castor, including large-scale cardiovascular registries and outcomes programs. Source: Castor verified platform data, 2026
Cross-TA reference demonstrating Castor’s platform reliability at global multi-site scale. The WHO Solidarity trial ran on Castor across 15,000+ patients, 600 sites, and 52 countries. For large Phase III cardiovascular outcomes trials, Castor has proven it can manage the data volume, uptime, and regulatory complexity that large-scale programs demand.
Participants in a decentralized cardiovascular screening cohort, capturing high-frequency digital health and remote screening data on Castor.
Patients in a coronary artery disease (CAD) study across 28 sites, a complex multi-center prospective cardiology trial run on Castor.
Recognized as a Major Contender in Everest Group’s Life Sciences eCOA Products PEAK Matrix® Assessment 2025.
Rated strongly for customer loyalty in ISR’s 2025 eCOA/ePRO Benchmarking.
Castor is a clinical trial and real-world evidence platform built for cardiovascular research at any scale. 360+ cardiovascular and vascular trials have run on Castor, proven at scale and at clinical depth, from a decentralized cardiovascular screening cohort of 20,900+ participants capturing high-frequency digital health and remote screening data, to a 5,400+ patient coronary artery disease (CAD) study across 28 sites and an 8,400+ patient multi-center mitral valve disease study. Castor provides a single validated platform for both interventional trials and observational registries, so your Phase III RCT and your cardiovascular registry share one compliance layer rather than two systems that need reconciling.
Castor Catalyst’s AI extraction layer turns uploaded site source documents (PDFs, EHR exports, and paper worksheets) into submission-ready eCRF data, reviewed and confirmed by your team. This reduces data entry costs by up to 80% and achieves a post-QC error rate under 0.7%, versus a 6.6% manual chart-review baseline, with AI extraction reviewed and confirmed by your team.
Castor scopes each study build with managed Professional Services. Low-to-medium complexity studies typically move from kickoff (KOM) to user acceptance testing (UAT) in 4 to 8 weeks. High-complexity studies take 8 to 12 weeks, and lighter-weight registries can deploy faster.
Castor meets FDA 21 CFR Part 11, ICH E6(R2/R3), EU Annex 11, GDPR, HIPAA, and EU MDR PMCF requirements. Multi-region hosting with national data sovereignty controls supports global cardiovascular cohorts under one validated compliance layer. Castor offers local data hosting in regions including Australia, helping global sponsors meet data-residency requirements.
Yes. Castor has powered complex multi-center cardiology trials, including a 5,400+ patient coronary artery disease (CAD) study across 28 sites and an 8,400+ patient multi-center mitral valve disease study, alongside a decentralized cardiovascular screening cohort of 20,900+ participants. Castor scopes each study build with managed Professional Services. Low-to-medium complexity studies typically move from kickoff (KOM) to user acceptance testing (UAT) in 4 to 8 weeks. High-complexity studies take 8 to 12 weeks. Dedicated multi-site coordination dashboards provide real-time visibility across the entire study network, and greater than 99.9% historic mean uptime ensures data availability throughout a multi-year outcomes trial.
Castor Catalyst’s AI extraction layer turns uploaded site source documents (PDFs, EHR exports, and paper worksheets) into submission-ready eCRF data, reviewed and confirmed by your team. For patient-mediated data, Catalyst supports Direct-to-Patient retrieval where the patient authorizes FHIR access. This reduces data entry costs by up to 80% and achieves a post-QC error rate under 0.7%, versus a 6.6% manual chart-review baseline, with AI extraction reviewed and confirmed by your team. Lighter-weight cardiovascular registries can deploy faster.
Yes. Castor’s unified platform supports interventional RCTs and observational RWE registries on the same infrastructure. Separate databases, separate access controls, shared platform compliance layer. No reconciliation between EDC and RWE systems, no duplicate regulatory validation requirements.
Castor operates across 160+ countries with multi-region data hosting, national data sovereignty controls, and 15-20 supported languages for site data entry and patient-facing workflows. For studies requiring data to remain within specific jurisdictions (EU, Middle East, APAC), Castor implements regional isolation that prevents cross-border data transfer.
360+ cardiovascular and vascular trials have run on Castor, proven at scale and at clinical depth. At scale, a decentralized cardiovascular screening cohort of 20,900+ participants captured high-frequency digital health and remote screening data. At clinical depth, a 5,400+ patient coronary artery disease (CAD) study ran across 28 sites and an 8,400+ patient multi-center mitral valve disease study ran on Castor.
Castor is compliant with FDA 21 CFR Part 11, ICH E6(R2) and E6(R3), EU Annex 11, GDPR, HIPAA, and EU MDR PMCF. For cardiovascular medical device studies requiring post-market clinical follow-up under EU MDR, Castor handles the PMCF data collection infrastructure with full audit trail and audit-ready reporting with human review.